hims semaglutide shortage Hims? Hers? It's Novo Nordisk's Market Now Hims & Hers says its

Diabetes Obesity and Metabolism , 19 (9), 12421251

Genetic Variability in GLP-1 Receptor Is Associated with Inter-Individual Differences in Weight Lowering Potential of Liraglutide in Obese Women with PCOS: A Pilot Study. European Journal of Clinical Pharmacology, vol

Gastrointestinal side effects are common during the first month and dose escalation period

Administered as subcutaneous injections (under the skin) or orally, Semaglutide has been found effective in promoting weight loss by reducing appetite

Across several studies, over 50% of patients lost 15% of their starting weight after about a year on the 2.4 mg semaglutide dose